my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
15-08-2012: Intelliject, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Auvi-Q™ (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.
Eric and Evan Edwards, twin brothers who jointly founded Intelliject and who themselves suffer from severe, life-threatening allergies, developed Auvi-Q with a team of engineers and scientists using a comprehensive Human Factors Engineering process. This development process incorporated real-world experiences and feedback from patients and caregivers.
“In developing Auvi-Q, our goal is to offer patients and caregivers an innovative treatment option that is easy to use in an emergency,” said Eric Edwards, Chief Science Officer, Intelliject, Inc. “As allergy sufferers, my twin brother and I know first-hand how stressful it can be when you experience a severe allergic reaction. Auvi-Q’s small size and intuitive design, as well as its first-in-class prompt system that talks a user through the injection process, will help patients and caregivers manage a life-threatening allergic reaction.”
Auvi-Q contains epinephrine, the well-established, first-line treatment for severe, life-threatening allergic reactions that may occur as a result of exposure to allergens including nuts, shellfish, dairy, eggs, insect bites, latex and medication, and others.
“The FDA approval of Auvi-Q is an important milestone for the company and is a result of our steadfast commitment to developing patient-centric products,” said Spencer Williamson, President and Chief Executive Officer, Intelliject, Inc. “We are building on this approval and have a pipeline of drug/device combination products for select therapy areas.”
Watchlist
This is where you can add this news to your personal favourites
Intelliject, Inc. Receives FDA Approval for Auvi-Q
Intelliject, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Auvi-Q™ (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-i ... more
Virginia BioTechnology Research Park announces new $300 million Phillip Morris project
The Virginia BioTechnology Research Park announced that Philip Morris USA will begin construction on a new $300 million research and technology center in the Park's downtown campus. The new facility will be Philip Morris USA's largest capital project since the 1980s, and will be the single ... more
Virginia lab records its 2,000th DNA cold hit
Richmond. The Virginia Division of Forensic Science has recently recorded its 2,000th DNA "cold hit" in a pioneering program that has helped solve murders, rapes and other crimes for more than a decade. A cold hit occurs when DNA in crime-scene evidence such as blood or hair matches DNA re ... more
Epigenomics submits the fourth module to the FDA for Epi proColon
Epigenomics AG announced that it has submitted the fourth and final module of its Premarket Approval (PMA) to the United States Food & Drug Administration (FDA) for its blood-based Epi proColon® test for the detection of colorectal cancer in December 2012 as previously indicated, thereby co ... more
FDA Approves Genzyme’s AUBAGIO (teriflunomide), a Treatment for Relapsing Multiple Sclerosis
Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). AUBAGIO has shown significant efficacy across key measures ... more
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), the first new granulocyte colony-stimulating factor (G-CSF) to be approved in the United States in more than 10 years. Tbo-filgrastim is ... more
U. S. Food and Drug Administration (FDA)
FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. FDA is also responsible for advancing the public hea ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
